Overview
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapeutics for diseases including diabetes, cancer, inflammatory, and autoimmune diseases. MannKind Corporation operates two business units, MannKind Immunology and MannKind Biopharmaceuticals. MannKind Immunology is focused on developing agents to treat cancer as well as a variety of inflammatory and autoimmune diseases. The corporate headquarters and MannKind Immunology are located in Valencia, California.
MannKind Biopharmaceuticals is located in Danbury, Connecticut, which is the location of our Technosphere® Insulin research, development and manufacturing. Our lead product candidate, which is currently in Phase IIb clinical trials, is a new-generation pulmonary insulin system for the treatment of diabetes. This system is based on our proprietary Technosphere® technology, which is being developed with the goal of providing a wide range of alternatives for non-invasive pulmonary drug delivery of therapeutic agents that currently require invasive administration.